5-Aminoimidazole-4-carboxamide ribonucleoside induces differentiation of acute myeloid leukemia cells

Leukemia & Lymphoma
Hrvoje LalicDora Visnjic

Abstract

Adenosine monophosphate (AMP)-activated kinase (AMPK) modulators have been shown to exert cytotoxic activity in hematological malignancies, but their role in the differentiation of acute myeloid leukemia (AML) is less explored. In this study, the effects of AMPK agonists on all-trans retinoic acid (ATRA)-mediated differentiation of acute promyelocytic leukemia (APL) and non-APL AML cell lines were investigated. The results show that AMPK agonists inhibit the growth of myeloblastic HL-60, promyelocytic NB4 and monocytic U937 cells. 5-Aminoimidazole-4-carboxamide ribonucleoside (AICAR), an AMPK activator, enhances ATRA-mediated differentiation of NB4 cells. In U937 cells, AICAR alone induces the expression of cell surface markers associated with mature monocytes and macrophages. In both cell lines, AICAR increases the activity of mitogen-activated protein kinase (MAPK), and the presence of a MAPK inhibitor reduces the expression of differentiation markers. These results reveal beneficial effects of AICAR in AML, including differentiation of non-APL AML cells.

References

Jan 13, 2006·Immunology and Cell Biology·John KanellisDavid A Power
Nov 28, 2006·Lancet·Elihu Estey, Hartmut Döhner
Sep 14, 2007·The Biochemical Journal·Jenny BainPhilip Cohen
Aug 5, 2008·Cell·Vihang A NarkarRonald M Evans
Nov 13, 2008·American Journal of Physiology. Endocrinology and Metabolism·Ippei KanazawaToshitsugu Sugimoto
May 27, 2009·British Journal of Haematology·Julian WampflerChristian Britschgi
Dec 30, 2009·The Journal of Clinical Investigation·Ismael SamudioMichael Andreeff
Sep 3, 2011·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Hong-Beom BaeEdward Abraham
Oct 25, 2011·Blood·Eliza VakanaLeonidas C Platanias
Dec 29, 2011·Oncotarget·Sonia Del BarcoJavier A Menendez
Jan 11, 2012·Nature Medicine·Johanna T LannerSusan L Hamilton
May 12, 2012·Biochemical and Biophysical Research Communications·Lei HuaiJianxiang Wang
Jul 17, 2012·The Journal of Clinical Investigation·Hanna S RadomskaDaniel G Tenen

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.